

Synthesis of daunosamyl anthraquinone and anthracyclinone analogs

Karsten Krohn,^{a*} Gabriele Carlson,^a Hannelore Köhle,^a Hidayat Hussain,^a
and Ivan R. Green^b

^a*Department of Chemistry, University of Paderborn, Warburger Straße 100, 33098 Paderborn, Germany*

^b*Department of Chemistry, University of the Western Cape, P/Bag x17, Bellville, 7530, South Africa*

E-mail: k.krohn@uni-paderborn.de

Abstract

Four groups of aglycones (cyclopenta-annulated anthraquinones, mono- and bis-hydroxyalkyl-anthraquinones, steffinyne) were glycosylated with daunosamine chloride. In all cases, the major products were the respective α -glycosides (α , β -ratio *ca.* 9:1). In some cases, the β -glycosides rearranged to furanosides under the glycosylation conditions.

Keywords: Glycosylation, non-natural anthracyclines, daunosamine, rearrangement

Introduction


New synthetic anthracyclines continue to be of great interest to overcome resistance and to reduce toxicity of these important anti-cancer drugs.¹ In connection with our work on the total synthesis of anthracyclinones (for reviews, see refs 2-13) and the aglycones of the important anthracycline antitumor antibiotics (for reviews, see refs 14-36), we started an investigation on the glycosylation of structurally diverse synthetic anthraquinone derivatives prepared by our group. (For a selection of other syntheses of anthracycline derivatives see refs 37-47). The general aim of this research was to get insight into the DNA binding capability as a function of distinct structural parameters and to correlate these binding data with cytotoxic activity. This investigation will be published elsewhere. In the present study we, describe the glycosylation step, the ratio of the α - to β -glycosides formed, and a new rearrangement of the *N*-trifluoroacetyl daunosamine β -glycosides to the respective furanoside glycosides. Trifluoroacetyl-protected daunosamine chloride **2** was used as the sugar component in all the reactions (Scheme 1). The activated protected sugar **2** was prepared from daunosamine hydrochloride, a gift from Prof. Arcamone, and was also prepared on a larger scale using the procedure of Horton and

Weckerle.⁴⁸ Silver triflate, introduced by Hanessian into glycosylation chemistry,⁴⁹ served as the catalyst, as described by Arcamone *et al.* in the early stages of synthetic anthracycline analogs.^{50a} Daunosamine was selected as the sugar component because previous work showed clearly that this sugar provided the essential stereochemical requirements for DNA binding and biological activity.⁵⁰⁻⁵²

Results and Discussion

The aglycones selected can be classified into four groups: (a) a tetracyclic cyclopenta-anthraquinone (Scheme 1), (b) mono-hydroxymethyl anthraquinones (Scheme 2), (c) bis-hydroxymethyl anthraquinones (Scheme 4), and (d) steffimycynone, an anthraquinone with an unusual substitution in ring D (Scheme 5).


The first aglycone, the cyclopenta-anthraquinone, *rac-1*, was prepared stereoselectively by reaction of leuco-quinizarine with α,β -unsaturated aldehydes such as methacrolein (see the Experimental Section). The *trans*-configuration of the methyl and hydroxyl group was deduced from the coupling constants of $J_{1,2} = 3.4$ Hz in the ¹H NMR spectrum. From the glycosylation of *rac-1*, only a single α -glycoside, **3**, was isolated in pure form and the assignment shown in Scheme 1 is tentative.



Scheme 1. Glycosylation of cyclopenta-anthraquinone *rac-1*.

The largest group of non-natural daunosamyl glycosides was prepared from achiral hydroxymethyl anthraquinones **4-10** and the chiral racemic 1-hydroxybutylanthraquinone, *rac-27*. The aglycones were readily prepared by a variation of the Marschalk reaction (reaction of dihydroanthraquinones with aldehydes) in which reductive elimination of the benzylic hydroxyl group was prevented by conducting the hydroxyalkylation of the dihydroanthraquinones at low temperature, with shorter reaction times, and with rapid re-oxidation of the dihydroquinones to the respective anthraquinones.⁵³⁻⁵⁶ The glycosylation reactions were studied in great detail in repeated reactions and by careful analysis of the reaction products. In the reaction of the enantiomerically pure halo-sugar **2** with the achiral hydroxymethyl anthraquinones **4-10**, only the

α -glycosides and the respective β -glycosides were expected. In fact, in many cases these two products (**11-17**: α -glycosides) and (**18-22**: β -glycosides) could be isolated, with the α -glycosides being mostly the less polar products (Scheme 2). However, careful analysis of some of the polar reaction products revealed a surprising phenomenon. The compounds **23-26** turned out to be furanosides as shown in Scheme 2. In two cases (aglycone **7** and **9**), no β -glycoside could be isolated from the reaction mixture. In contrast, all three possible products were isolated from the reaction of aglycones **8** and **10**. In the case of the chiral 1-hydroxybutyl-quinizarine *rac*-**27**, the glycosylation led to the diastereoisomeric α -glycosides **28** and **29**. The minor β -glycoside were not isolated in this case, and the stereochemical assignment is arbitrary.



Scheme 2. Glycosylation of achiral-(4-10) and racemic-(*rac*-27) hydroxyalkyl-anthraquinones.

The configuration of the furanosides **23-26** could in part be solved by comparison with the stereoisomeric methyl 2,3,6-trideoxy-3-(trifluoroacetamido)- β - and - α -*D*-ribo-hexo-furanosides, **A** and **B**, and the β - and α -*L*-lyxo-furanosides **C** and **D** (Scheme 3), prepared by El Khadem and Matsuura *via* the corresponding dithioacetals of epidaunosamin and daunosamine, respectively.⁵⁷ As can be seen from Table 1, in which the relevant ¹H NMR data of the furanosides **A-D** was obtained from the literature⁵⁷ are compared with those of our furanosides **23-26**, the coupling constant, $J = 4.0$ Hz, for the β -glycoside **A** compares well with that of our furanose glycosides (J


= 4.0-4.2). In addition, the corresponding signals for the anomeric protons of the α -glycosides **B** and **D** appear as multiplets with two different coupling constants (see Table 1). Thus, the β -configuration of our furanosides can be deduced unambiguously. On the assumption that the other stereocenters of the original daunosamine sugar did not change, the β -L *lyxo* configurations for **23-26** and **34** are proposed as shown in Schemes 2 and 4. The data shown in Table 1 also show the consistency of the relevant ^1H NMR data of the synthetic furanoses, demonstrating their stereochemical identity.

The mechanism of the rearrangement of the hexoses into the furanoses during the silver-promoted glycosylation is not yet clear. However, since the major α -pyranosides are stable under the reaction conditions, a rearrangement of the β -anomers during the glycosylation reaction, or the presence of a furanoside structure of the daunosamine halide, seems most probable.

Table 1. ^1H -NMR data for assignment of the configuration of the furanoses **23-26** and **34**

Cpd	Config.	1'-H; m, <i>J</i>	2'a-H	2'e-H	3'-H	4'-H	5'-H	6'-H
23	β	5.44; d, 4.2	2.05	2.32	4.55	3.88	3.84	1.28
24	β	5.44; d, 4.2	2.05	2.32	4.55	3.88	3.84	1.28
25	β	5.44; d, 4.2	2.05	2.32	4.55	3.88	3.84	1.30
26	β	5.45; d, 4.0	2.06	2.33	4.58	3.89	3.85	1.29
34	β	5.44; d, 4.0	2.08	2.28	4.53	3.86	3.83	1.27
A ^a	β	5.19; d, 4.0	1.79–2.54	1.79–2.54	4.64	3.66–4.11	3.40	1.23
B ^a	α	5.20; m, 1.5, 5.4	1.87–2.81	1.87–2.81	4.75	3.70–4.15	3.43	1.26
C ^a	β	5.20; -	1.76–2.52	1.76–2.52	4.52	3.69–4.01	3.46	1.27
D ^a	α	5.13; m, 2.3, 4.7	1.76–2.33	1.76–2.33	4.65	3.64–4.01	3.45	1.19


^a From reference 57.



Scheme 3. Structures of furanoses **A-D** prepared from daunosamine and epidaunosamine.⁵⁷


Two examples of bis-hydroxymethylated achiral anthraquinones **30** and **32** were reacted with an excess of the sugar halide **2**. The bis-glycosides are very attractive candidates to probe the possibility of stronger intercalation into double-stranded DNA. Since in principle each glycoside can appear in three different forms, a complex mixture was expected. However, to our delight, in the case of the 2,3-bis-hydroxymethyl-quinizarine **30**,⁵⁵ which has both hydroxymethyl groups

on the same side of the molecule, one major bis- α -glycoside **31** was isolated in highly pure form. However, in the case of bis-hydroxymethyl-1,5-dihydroxy-anthraquinone **32**,⁵⁴ where the two hydroxymethyl groups are on opposite sides and on different aryl rings of the molecular scaffold, careful analysis of the glycosylation products revealed the formation of two major products **33** and **34**. In the analogue **33**, both sugar moieties were attached in α -glycosidic form, whereas in the analogue **34**, one α -glycoside and one rearranged β -L-*lyxo*-furanoside were present in the same molecule.



Scheme 4. Glycosylation of bis-hydroxymethylated anthraquinones **30** and **32**.

Finally, the naturally occurring anthracyclinone steffimycinone, **35**,⁵⁸ was converted into the daunosamyl glycoside **36** by reaction with the halo-sugar **2** (Scheme 5). As expected, the homochiral aglycone was converted into one major α -glycoside, as seen from the ^1H NMR spectrum. Since the natural anthracycline steffimycin does not have an amino sugar moiety, for reasons of comparison, it was considered advantageous to have the homologous series of daunosamyl glycosides. In addition, the hybrid glycoside **34** offered the chance to probe the influence of the different substitution pattern of the hydroaromatic ring A, quite different from the standard daunorubicine, on DNA binding, and also to compare the amino-sugar glycoside **36** with the natural steffimycins⁵⁸ which have no amino-sugar moiety.



Scheme 5. Conversion of steffimycinone **35**, into the daunosamyl α -glycoside **36**.

In summary, the four groups of selected aglycones were converted into daunosamyl glycosides. In all cases, the major products were the α -glycosides (α : β -ratio *ca* 3-9:1). In five cases, the β -glycosides rearranged to β -L-*lyxo*-furanosides under the glycosylation conditions employed.

Experimental Section

General Procedures. Melting points were determined with an Electrothermal apparatus and are uncorrected. The IR spectra (KBr) were measured with a Perkin-Elmer 297, and the NMR spectra (CDCl_3) with a Bruker WH 270 (270 MHz) or Bruker Avance-500 NMR spectrometer, with TMS as internal standard (*mc* = centered multiplet). EI mass spectra were obtained on a MAT 8200 mass spectrometer at 70 eV. UV spectra were measured with a Perkin-Elmer Lambda 45 instrument and the UV/VIS data of representative compounds are listed in Table 2.

General procedure for glycoside synthesis.⁵¹ A solution (or suspension) of the respective aglycone in dry CH_2Cl_2 (distilled over P_2O_5) (10–30 mL) was treated first with a threefold molar excess of daunosamyl chloride (**2**), prepared according to the procedure of Horton and Weckerle.⁴⁸ Then a solution of silver trifluorosulfonate (threefold excess) in dry diethyl ether (2–5 mL) was added dropwise. The mixture was stirred under exclusion of light and monitored by TLC (for reaction times see the individual compounds). The reaction was quenched by addition of excess aq. NaHCO_3 solution (*ca.* 5 mL) and the organic phase was dried (Na_2SO_4) and evaporated at reduced pressure. To cleave the trifluoroacetate ester, the residue was dissolved in dry methanol (20 mL) and heated under reflux for 30 min. The solvent was removed under reduced pressure, the residue redissolved in CH_2Cl_2 (10 mL), washed twice with water (10 mL), dried (Na_2SO_4) and separated by preparative TLC (1 mm silica gel plates, Schleicher and Schüll). CH_2Cl_2 was normally used as the eluent; for more polar compounds 15–25 % of diethyl ether-, and for very polar compounds an additional 1–2 % of methanol, was added. The plates

were developed 15–20 times to separate the very similar isomeric glycosides. The major products usually consisted of the diastereomeric α -L-glycosides, and the minor components were either the β -L-glycosides or rearranged β -furanoside. Some of the glycosides could be crystallized from diethyl ether while others were precipitated with petroleum to afford a non-crystalline powder. These powders showed a melting range of 120–130 °C. All samples were dried for 6–7 h at 60 °C under high vacuum (1 mm Hg). In some cases, traces of solvent (CH₂Cl₂, diethyl ether) could not be removed completely without decomposition of the glycosides.

Table 2. UV/VIS data of representative chromophores

Compound	λ_{\max} / nm (log ₁₀ ϵ)
3	516 sh (3.75), 481 (3.98), 331 sh (3.41), 289 (3.97), 252 (4.16), 218 (3.15)
11	409 (2.83), 329 (3.51), 284 sh (4.09), 262 (4.17), 218 (4.15)
12	478 (4.05), 380 sh (3.47), 284 (4.00), 245 (4.19), 218 (4.19)
13	415 (4.01), 254 (4.24), 232 (4.20), 217 (4.23)
14	433 (4.05), 286 (4.10), 250 (4.19), 218 (4.18)
16	476 (4.05), 380 (3.48), 284 (3.99), 248 (4.21), 237 (4.21), 218 (4.21)
34	438 (4.10), 424 (4.10), 290 (3.06), 256 (4.33), 233 (4.31), 218 (4.32)

1,4,11-Trihydroxy-2-methylcyclopenta[*b*]anthracene-5,10-dione (*rac*-1). A solution of leucoquinizarine (9,10-dihydroquinizarine) (3.60 g, 15 mmol) in 1N NaOH (200 mL) had added a solution of methacrolein (1 mL) in methanol (20 mL), dropwise, under nitrogen at 0 °C. After stirring for 2 h at 0 °C, the solution was acidified by addition of 2N HCl (110 mL) and the precipitate was filtered off. The dried crude product was filtered through a short column of silica gel (15 x 3 cm; dichloromethane). The eluate was concentrated at reduced pressure to 10 mL and diluted with petroleum ether until a precipitate formed. After 14 h at 4 °C, 3.35 g (72 %) of the cyclopenta[*b*]anthraquinone *rac*-1 crystallized; mp 230–231 °C. IR: 3500 (OH), 1613 (quinone, chelated), 1583 cm⁻¹ (aromatic). ¹H NMR (270 MHz): δ = 1.32 (d, J = 7.0 Hz, 3H, CH₃), 2.40–2.76 (m, 2H, 2-H, 3-H), 2.93 (s, 1H, OH), 3.33 (m, 1H, 3-H), 5.11 (d, J = 3.8 Hz, 1H, 1-H), 7.83 (m, 2H, 7-H, 8-H), 8.33 (m, 2H, 6-H, 9-H), 13.03 (s, 1H, OH), 13.18 (s, 1H, OH). UV (methanol): λ_{\max} (log ϵ) = 250 (4.56), 2.88 (3.91), 449 (3.85), 4.78 (3.92), 512 nm (3.69). MS (160 °C): m/e = 311 (25 %, M + 1), 310 (97, M+), 294 (14), 293(35), 292 (100), 291 (36), 281 (11), 276 (35), 274 (14), 263 (13), 262 (10), 249 (12), 187 (11), 165 (13). Anal. Calcd for C₁₈H₁₄O₅ (310.31): C, 69.67; H, 4.55. Found: C, 69.77; H, 4.52%.

1-O-(2,3,6-Trideoxy-3-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-4,11-dihydroxy-2-methylcyclopenta[*b*]anthracene-5,10-dione (3**).** The aglycone *rac*-1 (82 mg, 0.2 mmol) was reacted as described in the General Procedure to afford 36 mg (34 %) of glycoside **3**; mp 302 °C. IR: 3420 (OH, NH), 1720, 1697 (C=O), 1620 (quinone, chelated), 1589 cm⁻¹ (Ar). ¹H NMR (500 MHz, CDCl₃): δ 1.21 (d, J = 7.1 Hz, 3H, 2-CH₃), 1.31 (d, J = 6.6 Hz, 3H, 6'-H), 1.82 (dt, J = 16.0, 13.0, 3.5 Hz, 1H, 2'b-H), 2.00 (m, 2H, 2'a-H), 2.54 (dd, J = 17.5, 4.6 Hz, 1H, 3b-H), 2.60

(m, 1H, 2-H), 3.38 (ddd, $J = 17.5, 7.5, 0.7$ Hz, 1H, 3a-H), 3.64 (br d, $J = 7.6, 6.5$ Hz, 1H, 4'-H), 4.23 (br q, $J = 6.5$ Hz, 1H, 5'-H), 4.40 (m, 1H, 3'-H), 4.95 (d, $J = 3.4$ Hz, 1H, 1-H), 5.48 (d, $J = 3.5$ Hz, 1H, 1'-H), 6.66 (br d, $J = 8.7$ Hz, 1H, NH), 7.80 (m, 2H, 7-H, 8-H), 8.35 (m, 6-H, 9-H), 13.00 (s, 1H, OH), 13.39 (s, 1H, OH); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 16.6$ (q, C-6'), 18.9 (q, CH_2CH_3), 29.6 (t, C-2'), 36.0 (t, C-3), 40.6 (d, C-2), 46.2 (d, C-3'), 65.9 (d, C-5'), 69.2 (d, C-4'), 86.5 (d, C-1), 97.4 (d, C-1'), 112.6 (s, C-11a), 113.2 (s, C-5a), 126.9 (s, C-5, C-8), 133.5 (s, C-11a), 133.6 (s, C-9a), 134.3 (d, C-8), 134.4 (d, C-7), 141.5 (s, C-13), 145.1 (s, C-4), 155.0 (s, C-12), 156.0 (s, C-5), 186.9 (s, C-11), 187.2 (s, C-10); EIMS (290 °C): m/z (%) = 535 (11) [M^+], 310 (100); 292 (94), 187 (36). HREIMS: m/z (%) = 535.1456 (Calcd. for, 535.1454). Anal. Calcd for $\text{C}_{26}\text{H}_{24}\text{NO}_8\text{F}_3$ (535.48): C, 58.32; H, 4.52; N, 2.62. Found: C, 58.07; H, 4.53; N, 2.59%.

1-Hydroxy-3-methyl-2-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (11). Aglycone **4**^{54,60} (200 mg, 0.75 mmol) was reacted according to the general procedure with daunosamyl chloride (**2**) (573 mg, 1.32 mmol) and silver triflate (410 mg, 1.59 mmol), to afford starting material (11 mg, 0.04 mmol) and the less polar α -glycoside **11** (282.8 mg, 81.4%), mp 238-239 °C. IR (KBr): 3450, 3300 (OH, NH), 2980, 2920 (CH), 1705 (C=O), 1685 (quinone), 1649 (quinone, chelated), 1595, 1560, 1357, 1185, 1025, 712 cm^{-1} . (500 MHz, CDCl_3): $\delta = 1.25$ (d, $J = 6.5$ Hz, 3H, 6'-H), 1.81 (ddd, $J = 12.5, 10.1, 3.5$ Hz, 1H, 2'-a-H), 1.98 (dd, $J = 12.5$ Hz, 4.5 Hz, 1H, 2'-e-H), 2.55 (s, 3H, 11-H), 3.59 (br d, $J = 5$ Hz, 1H, 4'-H), 4.20 (q, $J = 6.5$ Hz, 1H, 5'-H), 4.39 (m, 1H, 3'-H), 4.65 (d, $J = 11.0$ Hz, 1H, CH_2), 4.95 (d, $J = 11.0$ Hz, 1H, CH_2), 5.07 (d, $J = 3.5$ Hz, 1H, 1'-H), 6.69 (d, $J = 8.3$ Hz, 1H, 4'-NH), 7.69 (s, 1H, 4-H), 7.82 (m, 2H, 6-H, 7-H), 8.32 (m, 2H, 5-H, 8-H), 13.12 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, CDCl_3): $\delta = 16.6$ (q, C-6'), 20.3 (q, 3- CH_3), 29.8 (t, C-2'), 46.2 (d, C-3'), 59.6 (d, C-5'), 65.8 (t, CH_2), 69.2 (C-4'), 96.7 (d, C-1'), 114.6 (s, C-1a), 121.4 (d, C-4), 126.9 (d, C-6), 127.4 (d, C-7), 130.6 (s, C-4a), 132.5 (s, C-2), 133.3 (s, C-9a), 133.6 (d, C-10a), 134.2 (s, C-6), 134.5 (d, C-7), 149.0 (s, C-3), 161.6 (C-1), 182.5 (s, C-9), 188.3 (s, C-10). EIMS (290 °C): m/z (%) = 493 (3) [M^+], 268 (93); 252 (100), 239 (33), 165 (20), 113 (25). HREIMS: m/z (%) = 493.1348 (Calcd. for $\text{C}_{24}\text{H}_{22}\text{F}_3\text{NO}_7$, 493.1357).

2-[*O*-(2,3,6-Trideoxy-3-trifluoroacetamido- α -L-lyxo-hexopyranosyl)methyl]-1,4-dihydroxy-9,10-anthraquinone (12). Aglycone **5** (2-hydroxymethyl-quinizarin)^{54,55} (78 mg, 0.29 mmol) was reacted as described in the general procedure to afford 94 mg (66 %) of the α -glycoside **12**; mp 230 - 231 °C. IR: 3420 (OH, NH), 1716, 1696 (C=O), 1620 (quinone, chelated), 1588 cm^{-1} (arom.). ^1H NMR (270 MHz): $\delta = 1.30$ (d, $J = 6.7$ Hz, 3H, 6'-H), 1.88 (dt, $J = 13.4, 3.7$ Hz, 1H, 2'-a-H), 2.13 (dd, $J = 13.4, 5.4, 0.8$ Hz, 1H, 2'-e-H), 3.67 (m, 1H, 4'-H), 4.20 (q, $J = 6.7$ Hz, 1H, 5'-H), 4.54 (m, 1H, 3'-H), 4.69 (dd, $J = 14.5, 1.1$ Hz, 1H, 11-H), 4.89 (dd, $J = 14.5, 1.0$ Hz, 11-H), 5.10 (br d, $J = 3.7$ Hz, 1H, 1'-H), 7.49 (s, 1H, 3-H), 7.86 (m, 2H, 6-H, 7-H), 8.36 (m, 2H, 5-H, 8-H), 12.78 (s, 1H, OH), 13.31 (s, 1H, OH). EIMS (200 °C): m/z (%) = 495 (0.5) [M^+], 300 (100), 282 (35). Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{NO}_8\text{F}_3$ (495.41): C, 55.76; H, 4.07; N, 2.83. Found: C, 55.50; H, 3.86; N, 3.07.

1-Hydroxy-8-methoxy-2-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (13). Aglycone **6**⁶¹ (255 mg, 0.898 mmol) was glycosylated

as described in the general procedure (sugar chloride **2**:567.6 mg, silver triflate: 510 mg (1.98 mmol) to afford the α -glycoside **13** (321.3 mg, 86.4%); mp 229.5-231.5 °C. IR: 3530, 3280 (OH, NH), 2920 (-CH), 1700 (CO), 1670 (quinone), 1630 (quinone, chelated), 1585, 1430, 1280, 1170, 1070, 745 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 1.26 (d, J = 6.6 Hz, 3H, 6'-H), 1.85 (ddd, J = 13.6, 12.7, 3.2 Hz, 1H, 2'a-H), 1.92 (d, J = 8.6 Hz, 1H, 4'-OH), 2.08 (dd, J = 13.6, 4.9 Hz, 1H, 2'e-H), 3.63 (d, J = 8.6 Hz, 1H, 4'-H), 4.09 (s, 3H, OCCH_3), 4.16 (q, J = 6.6 Hz, 1H, 5'-H), 4.51 (m, 1H, 3'-H), 4.66 (d, J = 14.0 Hz, 1H, CH_2), 4.89 (d, J = 14.0 Hz, 1H, CH_2), 5.07 (d, J = 3.2 Hz, 1H, 1'-H), 6.67 (d, J = 8.4 Hz, 1H, 4'-NH), 7.38 (dd, J = 8.6, 1.0 Hz, 1H, 7-H), 7.77 (dd, J = 8.6, 7.7 Hz, 1H, 6-H), 7.78 (d, J = 7.7 Hz, 1H, 3-H), 7.81 (d, J = 7.7 Hz, 1H, 4-H), 7.99 (dd, J = 7.7, 1.0 Hz, 1H, 5-H), 13.32 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, DMSO-d_6): δ = 17.4 (q, C-6'), 28.8 (t, C-2'), 47.4 (d, C-3'), 57.0 (q, OCH_3), 63.0 (d, C-5'), 66.8 (t, CH_2), 67.2 (C-4'), 96.8 (d, C-1'), 115.2 (s, C-1a), 117.4 (s, C-10a), 118.3 (d, C-7), 119.7 (d, C-5), 119.8 (d, C-4), 131.7 (d, C-6), 134.4 (s, C-4a), 134.6 (s, C-9a), 136.9 (d, C-3), 159.4 (s, C-8), 161.1 (C-1), 182.2 (s, C-9), 188.8 (s, C-10). EIMS (300 °C): m/z (%) = 509 (0.1) [M^+], 284 (51), 268 (100), 250 (41), 113 (32). HREIMS: m/z (%) = 509.1298 (Calcd. for $\text{C}_{24}\text{H}_{22}\text{F}_3\text{NO}_8$, 509.1298).

1,8-Dihydroxy-2-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (14). Aglycone **7**⁵⁴ (300 mg, 1.11 mmol) was glycosylated as described in the general procedure using 854 mg (1.97 mmol) of halogenose **2**, and 614.1 mg (2.39 mmol) of silver triflate; reaction time 1 h; 17 mg (0.063 mmol) of aglycone **7** was recovered (94% conversion). Yield of α -glycoside **14**: 343.1 mg (62.2%) mp 254-255 °C. IR: 3500, 3280 (OH, NH), 2900 (-CH), 1700 (CO), 1670 (quinone), 1625 (quinone, chelated), 1552, 1430, 1285, 1175, 1073, 748 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 1.27 (d, J = 6.6 Hz, 3H, 6'-H), 1.88 (ddd, J = 12.6, 3.6, 2.5 Hz, 1H, 2'a-H), 2.10 (dd, J = 12.6, 5.2 Hz, 1H, 2'e-H), 3.66 (br s, 1H, 4'-H), 4.16 (q, J = 6.6 Hz, 1H, 5'-H), 4.51 (dddd, J = 12.6, 8.4, 5.2, 2.1 Hz, 1H, 3'-H), 4.65 (d, J = 14.0 Hz, 1H, CH_2), 4.88 (d, J = 14.0 Hz, 1H, CH_2), 5.07 (d, J = 3.3 Hz, 1H, 1'-H), 6.70 (d, J = 8.4 Hz, 1H, 4'-NH), 7.70 (t, J = 7.8 Hz, 1H, 6-H), 7.32 (d, J = 7.8 Hz, 1H, 4-H), 7.87-7.82 (m, 3H, 4-H, 5-H, 7-H), 12.03 (s, 1H, OH), 12.42 (s, 1H, OH); ^{13}C NMR (125 MHz, CDCl_3): δ = 16.6 (q, C-6'), 29.7 (t, C-2'), 46.2 (d, C-3'), 63.5 (d, C-5'), 65.9 (t, CH_2), 69.1 (C-4'), 96.7 (d, C-1'), 114.6 (s, C-1a), 117.4 (s, C-10a), 119.8 (d, C-5), 120.1 (d, C-4), 124.6 (d, C-7), 132.7 (d, C-6), 133.7 (s, C-4a), 133.8 (s, C-9a), 135.5 (d, C-3), 159.9 (s, C-8), 162.6 (C-1), 181.5 (s, C-9), 193.4 (s, C-10). EIMS (300 °C): m/z (%) = 495 (2) [M^+], 270 (95); 253 (100), 226 (28), 113 (76). HREIMS: m/z (%) = 495.1141 (Calcd. for $\text{C}_{23}\text{H}_{20}\text{F}_3\text{NO}_8$, 495.1141).

1,5-Dimethoxy-4-hydroxy-3-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (15). The glycosylation of aglycone **8**⁵⁹ (190 mg, 0.605 mmol) was performed as described in the general procedure using 571.8 mg (1.32 mmol) of sugar chloride **2**, and 405 mg of silver triflate (1.57 mmol), reaction time 4 h: yields; recovered starting material **8**, 1.3 mg (0.034 mmol) (conversion 95%); α -glycoside **15**, (168.3 mg, 54.5%) mp 256-258 °C; β -glycoside **21**, 32 mg (10.3%), mp 263-265 °C; and rearranged furanoside **24**, 30 mg (9.8 %). IR: 3495, 3290, (OH, NH), 2980, 2940, 2850 (-CH), 1700 (CO), 1655 (quinone), 1630 (quinone, chelated), 1588, 1425, 1280, 1255, 1197, 765 cm^{-1} . ^1H NMR

(500 MHz, CDCl₃): δ = 1.29 (d, J =6.9 Hz, 3H, 6'-H), 1.90 (ddd, J = 13.0, 12.5, 3.6 Hz, 1H, 2'-a-H), 2.03 (br s, 1H, 4'-OH), 2.09 (dd, J = 13.0, 5.0 Hz, 1H, 2'e-H), 3.66 (dd, J = 8.0, 2.5 Hz, 1H, 4'-H), 4.05 (s, 3H, OCH₃), 4.08 (s, 3H, OCH₃), 4.16 (q, J = 6.9 Hz, 1H, 5'-H), 4.54 (m, 1H, 3'-H), 4.67 (dd, J = 14.9, 1.2 Hz, 1H, CH₂), 4.92 (dd, J = 14.9, 1.2 Hz, 1H, CH₂), 5.08 (d, J = 3.6 Hz, 1H, 1'-H), 6.76 (d, J = 8.4 Hz, 1H, 3'-NH), 7.30 (dd, J = 8.3, 1.1 Hz, 1H, 6-H), 7.51 (s, 1H, 2-H), 7.75 (dd, J = 8.3 Hz, J = 8 Hz, 1H, 7-H), 7.95 (dd, J = 8.0, 1.1 Hz, 8-H), 13.52 (s, 1H, OH); ¹³C NMR (125 MHz, DMSO-d₆): δ = 17.3 (q, C-6'), 28.3 (t, C-2'), 47.3 (d, C-3'), 57.0 (q, OCH₃), 57.1 (q, OCH₃), 62.9 (d, C-5'), 67.0 (t, CH₂), 67.3 (C-4'), 96.8 (d, C-1'), 115.2 (s, C-1a), 116.3 (d, C-7), 117.5 (d, C-5), 117.7 (s, C-10a), 118.4 (d, C-3), 119.3 (s, C-4a), 136.6 (s, C-2), 136.9 (d, C-6), 136.6 (s, C-9a), 153.4 (s, C-1), 154.0 (s, C-4), 160.6 (s, C-8), 180.8 (s, C-9), 188.8 (s, C-10). MS: m/z (%) = 539 (10) [M⁺], 481 (0.5), 418 (2), 384 (12), 314 (64), 265 (13), 251 (22), 193 (19), 137 (24), 121 (100), 57 (28). HREIMS: m/z = 539.1403 (Calcd. for C₂₅H₂₄F₃NO₉, 539.1403).

1,4-Dihydroxy-5-methoxy-3-[1-O-(2',3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (16) and the isomeric rearranged furanoside 25.

Aglycone **9**⁵⁹ (200 mg, 0.67 mmol) was glycosylated as described in the general procedure using sugar **2** (512 mg, 1.18 mmol) and 350 mg (1.43 mmol) of silver triflate, reaction time 1h; yields: recovered aglycone **9** (25.5 mg, 0.085 mmol) (87% conversion), α -glycoside **16**: 209.1 mg (68.4%), mp 276-277 °C and rearranged β -glycoside **25**: 49.3 mg (16.1%), mp 219-221 °C. IR: 3530, 3270 (OH, NH), 2920 (-CH), 1700 (CO), 1615, 1580 (quinone, chelated), 1445, 1425, 1295, 1252, 1190, 1155, 1057 cm⁻¹. ¹H NMR (400 MHz): δ = 1.27 (d, J = 6.9 Hz, 3H, 6'-H), 1.88 (ddd, J = 13.2, 12.9, 4.0 Hz, 1H, 2'-a-H), 2.00 (d, J = 7.3 Hz, 1H, 4'-OH), 2.12 (dd, J = 13.2, 5.1 Hz, 1H, 2'e-H), 3.66 (dd, J = 7.3, 3.5 Hz, 1H, 4'-H), 4.11 (s, 3H, OCH₃), 4.15 (q, J = 6.9 Hz, 1H, 5'-H), 4.51 (dddd, J = 12.9, 8.0, 5.1, 3.5 Hz, 1H, 3'-H), 4.67 (d, J = 15 Hz, 1H, CH₂-Bridge), 4.87 (d, J = 15 Hz, 1H, CH₂), 5.07 (d, J = 4 Hz, 1H, 1'-H), 6.74 (d, J = 8.0 Hz, 1H, 3'-NH), 7.26 (s, 1H, 2-H), 7.40 (dd, J = 8.9, 1.0 Hz, 1H, 6-H), 7.80 (dd, J = 8.9, 7.5 Hz, 1H, 7-H), 8.05 (d, J = 7.5 Hz, 1H, 8-H), 12.90 (s, 1H, OH), 13.64 (s, 1H, OH). EIMS (180 °C): m/z (%) = 525 (18) [M⁺], 300 (100), 282 (88), 271 (17), 113 (18). HREIMS: m/z (%) = 525.1247 (Calcd. for C₂₄H₂₂F₃NO₉, 525.1247).

1,4,5-Trihydroxy-3-[1-O-(2',3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (17).

Aglycone **10** (250 mg, 0.87 mmol) was glycosylated as described in the general procedure using 640 mg (1.47 mmol) of sugar **2** (450 mg, 1.75 mmol) and 250 mg (0.87 mmol) of silver triflate; reaction time 1 h. After chromatographic separation, 45.6 mg (0.159 mmol) of aglycone **10** was recovered (conversion 82%). Yield of **17**, 195.7 mg (53.6%), mp 246-248 °C; β -glycoside **22**: 19.6 mg (5.4 %), mp 227; rearranged furanoside β -glycoside **26**: 42.9 mg (11.7%), mp 205-207 °C. Data for **17**: IR, 3500, 3420 OH, NH), 2980, 2900 (-CH), 1715 (CO), 1605 (quinone, chelated), 1435, 1275, 1172, 982, 770 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ = 1.25 (d, J = 6.4 Hz, 3H, 6'-H), 1.89 (ddd, J = 13.0, 12.8, 3.5 Hz, 1H, 2'-a-H), 1.95 (d, 8.2 Hz, 1H, 4'-OH), 2.11 (dd, J = 13, 5.0 Hz, 1H, 2'e-H), 3.65 (br d, J = 2 Hz, 1H, 4'-H), 4.14 (q, J = 6.4 Hz, 1H, 5'-H), 4.51 (m, 1H, 3'-H), 4.65 (d, J = 14.7, 1.5 Hz, 1H, CH₂), 4.86

(dd, $J = 14.7, 1.5$ Hz, 1H, CH₂), 5.07 (d, $J = 3.5$ Hz, 1H, 1'-H), 6.69 (d, $J = 7.9$ Hz, 1H, 3'-NH), 7.31 (dd, $J = 7.8, 1.0$ Hz, 1H, 6-H), 7.45 (s, 1H, 2-H), 7.71 (t, $J = 7.8$ Hz, 1H, 7-H), 7.88 (dd, $J = 7.8, 1.0$ Hz, 1H, 8-H), 12.16 (s, 1H, OH), 12.64 (s, 1H, -OH), 13.03 (s, 1H, -OH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 16.6$ (q, C-6'), 29.6 (t, C-2'), 46.1 (d, C-3'), 63.4 (d, C-6'), 66.0 (d, CH₂), 69.0 (C-4'), 96.7 (d, C-1'), 111.9 (s, C-10a), 112.4 (s, C-4a), 119.5 (d, C-8), 124.6 (d, C-6), 126.1 (d, C-3), 127.0 (d, C-5), 127.1 (d, C-8), 133.2 (s, C-9a), 133.4 (d, C-2), 134.2 (d, C-7), 137.1 (d, C-7), 155.4 (s, C-1), 158.3 (s, C-4), 162.7 (C-5), 185.9 (s, C-9), 191.4 (s, C-10). EIMS (260 °C): m/z (%) = 511 (8) [M⁺], 286 (100); 269 (82), 241 (24), 113 (18). HREIMS: m/z (%) = 511.1090 (Calcd. for C₂₃H₂₀F₃NO₉, 511.1090).

1-Hydroxy-3-methyl-2-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (18). From the same reaction (see 11), 19.2 mg (5.7%) of the more polar β -glycoside 18 was isolated, mp 250-251 °C. IR: 3520, 3285 (OH, NH), 2990, 2895 (-CH), 1700 (CO), 1670 (quinone), 1645 (quinone, chelated), 1595, 1560, 1365, 1292, 1187, 1176, 1060, 720 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): $\delta = 1.35$ (d, $J = 6.5$ Hz, 3H, 6'-H), 1.58 (ddd, $J = 13.0, 11.0, 10.0$, 1H, 2'a-H), 2.06 (ddd, $J = 13.0, 4.9, 2.2$ Hz, 1H, 2'a-H), 2.14 (s, 1H, 4'-OH), 2.53 (s, 3H, 11-H), 3.53 (d, $J = 9.7$ Hz, 1H, 4'-H), 3.70 (q, $J = 6.5$ Hz, 1H, 5'H), 4.11 (m, 1H, 3'-H), 4.65 (dd, $J = 10.0, 2.2$ Hz, 1H, 1' H), 4.94 (d, $J = 11.5$ Hz, 1H, CH₂), 5.02 (d, $J = 11.5$ Hz, 1H, CH₂), 6.76 (d, $J = 8.1$ Hz, 1H, 3'-NH), 7.70 (s, 1H, 4-H), 7.82 (m, 2H, 6-H, 7-H), 8.33 (m, 2H, 5-H, 8-H), 13.13 (s, 1H, 1-OH); ¹³C NMR (125 MHz, CDCl₃ + CD₃OD): $\delta = 16.3$ (q, C-6'), 20.0 (q, 3-CH₃), 30.9 (t, C-2'), 48.9 (d, C-3'), 60.7 (d, C-5'), 67.7 (t, CH₂), 71.8 (C-4'), 99.6 (d, C-1'), 114.0 (s, C-1a), 121.3 (d, C-4), 126.8 (d, C-6), 127.2 (d, C-7), 130.3 (s, C-4a), 132.5 (s, C-2), 133.2 (s, C-9a), 133.4 (d, C-10a), 134.2 (s, C-6), 134.5 (d, C-7), 149.1 (s, C-3), 161.3 (C-1), 182.7 (s, C-9), 188.2 (s, C-10). EIMS (180 °C): m/z (%) = 493 (0.1) [M⁺], 268 (74), 252 (100), 239 (27), 113 (12). HREIMS: m/z (%) = 493.1347 (Calcd. for C₂₄H₂₂F₃NO₇, 493.1348).

1,4-Dihydroxy-2-[*O*-(2,3,6-trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexopyranosyl)methyl]-9,10-anthraquinone (19). From the same reaction of aglycone 5 (see 12), 9 mg (6 %) of the more polar β -glycoside 19 was isolated; mp 244 °C. IR: 3420 (OH, NH); 1716, 1690 (C=O); 1624 (quinone, chelated), 1588 cm⁻¹ (aromat). ¹H NMR (500 MHz, CDCl₃): $\delta = 1.34$ (d, $J = 6.7$ Hz, 3H, 6'-H), 1.74 (dq, $J = 13.2, 12.6, 9.5$ Hz, 1H, 2a-H), 2.23 (ddd, $J = 13.2, 5.0, 2.1$ Hz, 1H, 2'e-H), 3.56 (br d, $J = 4.0$ Hz, 1H, 4'-H), 3.72 (dq, $J = 6.7, 1.0$ Hz, 1H, 5'-H), 4.18 (m, 1H, 3'-H), 4.71 (dd, $J = 10, 2.5$ Hz, 1H, 1'-H), 4.82 (dd, $J = 15.0, J = 1.0$ Hz, 1H, 11b-H), 5.08 (dd, $J = 15.0, 1.0$ Hz, 1H, 11a-H), 6.87 (d, $J = 7.8$ Hz, 1H, NH), 7.45 (s, 1H, 3-H), 7.85 (m, 2H, 6-H, 7-H), 8.37 (m, 2H, 5-H, 8-H), 12.90 (s, 1H, -OH), 13.26 (s, 1H, -OH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 16.3$ (q, C-6'), 29.7 (t, C-2'), 49.1 (d, C-3'), 65.0 (d, C-5'), 68.4 (d, C-4'), 71.5 (d, C-4'), 99.8 (d, C-1'), 111.8 (s, C-10a), 112.4 (s, C-4a), 126.4 (d, C-5), 127.0 (d, C-8), 133.6 (s, C-9a), 133.7 (s, C-8a), 134.4 (d, C-7), 134.6 (d, C-6), 139.4 (d, C-3), 144.2 (s, C-2), 155.2 (s, C-4), 157.8 (s, C-1), 186.1 (s, C-10), 187.3 (s, C-9). EIMS (180 °C): m/z (%) = 495 (7) [M⁺], 477 (1), 421 (05), 346 (0.5), 308 (0.5), 296 (2), 270 (100), 252 (71), 225 (18), 196 (7), 168 (5), 140 (7), 113 (13), 86 (10). HREIMS: $m/z = 495.1143$ (Calcd. for C₂₉H₂₈F₃NO₁₂, 495.1141).

1-Hydroxy-8-methoxy-2-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (20). From the same reaction (see **13**), the corresponding β -glycoside **20** was isolated; yield, 29 mg (7.8%), mp 249.5-251.5 °C. IR: 3550, 3290 (OH, NH), 2920 (-CH), 1710 (CO), 1665 (quinone), 1630 (quinone, chelated), 1580, 1430, 1277, 1170, 1070, 745 cm^{-1} . ^1H NMR (500 MHz, CDCl_3): δ = 1.35 (d, J = 6.5 Hz, 3H, 6'-H), 1.70 (ddd, J = 13.0, 12.5, 9.7 Hz, 1H, 2'a-H), 2.20 (ddd, J = 12.9, 4.9, 2.2 Hz, 1H, 2'e-H), 3.54 (br s, 1H, 4'-H), 3.69 (q, J = 6.5 Hz, 1H, 5'-H), 4.17 (m, 1H, 3'-H), 4.09 (s, 3H, OCH_3), 4.70 (dd, J = 10.0, 2.2 Hz, 1H, 1'-H), 4.84 (d, J = 14.2 Hz, 1H, CH_2), 5.06 (d, J = 14.2 Hz, 1H, CH_2), 6.80 (d, J = 8.5 Hz, 1H, 3'-NH), 7.37 (dd, J = 7.5, 1.0 Hz, 1H, 7-H), 7.75 (d, J = 7.8 Hz, 1H, 3-H), 7.77 (t, J = 7.5 Hz, 1H, 6-H), 7.79 (d, J = 7.8 Hz, 1H, 4-H), 7.99 (dd, J = 7.7 Hz, 1.0 Hz, 1H, 5-H), 13.32 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, CDCl_3): δ = 16.6 (q, C-6'), 31.5 (t, C-2'), 49.2 (d, C-3'), 56.7 (q, OCH_3), 65.3 (d, C-5'), 68.5 (t, CH_2), 71.5 (C-4'), 99.8 (d, C-1'), 116.4 (s, C-1a), 118.2 (d, C-7), 118.5 (s, C-10a), 120.2 (d, C-5), 120.8 (d, C-4), 131.7 (d, C-6), 133.8 (s, C-4a), 134.0 (s, C-9a), 135.9 (d, C-3), 159.7 (s, C-8), 161.0 (C-1), 182.5 (s, C-9), 189.2 (s, C-10). EIMS (180 °C): m/z (%) = 509 (4) [M^+], 284 (91), 268 (100), 250 (23). HREIMS: m/z (%) = 509.1298 (Calcd. for $\text{C}_{24}\text{H}_{22}\text{F}_3\text{NO}_8$, 509.1298).

1,5-Dimethoxy-4-hydroxy-3-[1-*O*-(2',3',6'-Trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (21). From the same reaction of aglycone **8**⁶⁰ (see **15**) (190 mg, 0.605 mmol), the β -glycoside **21** (32 mg, 10.3%) was isolated; mp 263-265 °C. IR: 3420, 3290 (OH, NH), 2940 (-CH), 1705 (CO), 1665 (quinone), 1630 (quinone, chelated), 1585, 1425, 1250, 1160 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ = 1.30 (d, J = 6.5 Hz, 3H, 6'-H), 1.75 (ddd, J = 13.0, 12.5, 9.8 Hz, 1H, 2'a-H), 2.14 (d, J = 9.7 Hz, 1H, 4'-OH), 2.28 (ddd, J = 13.0, 2.3, 4.2 Hz, 1H, 2'e-H), 3.58 (d, J = 9.7 Hz, 1H, 4'-H), 3.73 (q, J = 6.5 Hz, 1H, 5'-H), 4.63 (s, 3H, OCH_3), 4.08 (s, 3H, OCH_3), 4.16 (ddd, J = 12.5, 8.3, 4.2 Hz, 1H, 3'-H), 4.73 (dd, J = 9.8, 2.3 Hz, 1H, 1'-H), 4.32 (d, J = 14.9 Hz, 1H, CH_2), 5.11 (d, J = 14.9 Hz, 1H, CH_2), 6.86 (d, J = 8.3 Hz, 1H, 3'-NH), 7.44 (dd, J = 8.8, 1.0 Hz, 1H, 6-H), 7.50 (s, 1H, 2-H), 7.75 (dd, J = 8.8, 8.0 Hz, 1H, 7-H), 7.98 (dd, J = 8.0, 1.0 Hz, 1H, 8-H), 13.51 (s, 1H, 4-OH). HREIMS: m/z = 539.1401 (Calcd. for $\text{C}_{25}\text{H}_{24}\text{F}_3\text{NO}_9$, 539.1403).

1,4,5-Trihydroxy-3-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (22). (See reaction for **17**). ^1H NMR (500 MHz, CDCl_3): δ = 1.35 (d, J = 6.4 Hz, 3H, 6'-H), 1.75 (ddd, J = 13.0, 12.8, 3.5 Hz, 1H, 2'a-H), 2.07 (d, J = 8.2 Hz, 1H, 4'-OH), 2.20 (dd, J = 13.0, 5.0 Hz, 1H, 2'e-H), 3.56 (br d, J = 2 Hz, 1H, 4'-H), 3.72 (q, J = 6.4 Hz, 1H, 5'-H), 4.20 (m, 1H, 3'-H), 4.71 (dd, J = 10.0, 2.5 Hz, 1H, 1'-H), 4.80 (d, J = 14.7, 1.5 Hz, 1H, CH_2), 5.07 (dd, J = 14.7, 1.5 Hz, 1H, CH_2), 6.82 (d, J = 7.9 Hz, 1H, 3'-NH), 7.31 (dd, J = 7.8, 1.0 Hz, 1H, 6-H), 7.46 (s, 1H, 2-H), 7.71 (t, J = 7.8 Hz, 1H, 7-H), 7.89 (dd, J = 7.8, 1.0 Hz, 1H, 8-H), 12.15 (s, 1H, OH), 12.62 (s, 1H, -OH), 13.01 (s, 1H, -OH); ^{13}C NMR (125 MHz, CDCl_3): δ = 16.6 (q, C-6'), 29.7 (t, C-2'), 49.1 (d, C-3'), 65.0 (d, C-6'), 68.5 (d, CH_2), 71.5 (C-4'), 99.9 (d, C-1'), 111.7 (s, C-10a), 112.0 (s, C-4a), 119.5 (d, C-8), 124.6 (d, C-6), 127.0 (d, C-5, C-8), 133.2 (s, C-9a), 133.7 (d, C-6, C-7), 134.2 (d), 137.1 (d, C-3), 155.2 (s, C-1), 158.3 (s, C-4), 162.7 (C-5), 185.9 (s, C-9), 191.4 (s, C-10). EIMS (180 °C): m/z (%) = 525 (19) [M^+], 451 (2),

418 (1), 368 (1), 312 (4), 300 (100), 282 (83), 266 (20), 255 (17), 238 (10), 169 (8), 155 (10), 140 (16), 86 (24). HREIMS: $m/z = 525.1247$ (Calcd. for $C_{24}H_{22}F_3NO_9$, 525.1247).

1,8-Dihydroxy-2-[1-*O*-(2',3',6'-Trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexofuranosyl)-methyl]-9,10-anthraquinone (23). From the same reaction (see 14) was isolated the rearranged β -glycoside 23, yield: 37.7 mg (7.3%), mp 191-193 °C. IR: 3400, 3290 (OH, NH), 2980, 2920 (-CH), 1710 (CO), 1670 (quinone), 1625 (quinone, chelated), 1560, 1430, 1285, 1182, 1070, 743 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): $\delta = 1.30$ (d, $J = 6$ Hz, 3H, 6'-H), 2.00 (d, $J = 5.5$ Hz, 1H, 5'-OH), 2.04 (d, $J = 13.5$ Hz, 1H, 2'a-H), 2.30 (ddd, $J = 13.5, 7.7, 4.2$ Hz, 1H, 2'e-H), 3.84 (ddq, $J = 5.5, 6.0, 4.8$ Hz, 1H, 5'-H), 3.88 (br d, $J = 4.8$ Hz, 1H, 4'-H), 4.52 (br d, $J = 7.7$ Hz, 1H, 3'-H), 4.57 (d, $J = 12.2$ Hz, 1H, CH_2) 5.01 (d, $J = 12.2$ Hz, 1H, CH_2), 5.45 (d, $J = 4.2$ Hz, 1H, 1'-H), 7.30 (d, $J = 8.7$ Hz, 1 H, 3-H), 7.39 (d, $J = 8.0$ Hz, 1H, 3'-NH), 7.73 (m, 2H, 6-H, 7-H), 7.86 (m, 2H, 4-H, 5-H), 11.98 (s, 1H, OH), 12.58 (s, 1H, OH); ^{13}C NMR (125 MHz, $CDCl_3$): $\delta = 16.6$ (q, C-6'), 38.9 (t, C-2'), 50.9 (d, C-3'), 64.1 (d, C-5'), 68.4 (t, CH_2), 89.8 (C-4'), 103.9 (d, C-1'), 115.7 (s, C-1a), 115.8 (s, C-10a), 117.0 (d, C-7), 119.7 (d, C-5), 120.2 (d, C-4), 124.6 (d, C-7), 133.1 (d, C-6), 133.6 (s, C-4a), 136.5 (s, C-9a), 137.5 (d, C-3), 160.5 (s, C-8), 162.7 (C-1), 181.4 (s, C-9), 193.3 (s, C-10). EIMS (180 °C): m/z (%) = 495 (2) [M+], 415, (2), 344 (5), 312 (6), 270 (42), 253 (100), 224 (27), 113 (58). HREIMS: m/z (%) = 495.1141 (Calcd. for $C_{23}H_{20}F_3NO_8$, 495.1141).

1,5-Dimethoxy-4-hydroxy-3-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexofuranosyl)-methyl]-9,10-anthraquinone (24). From the same reaction of aglycone 8⁶⁰ (see 15) the furanosyl-glycoside 24 (29 mg, 9.3%) was isolated. mp 226.227 °C. IR: 3420, 3290 (OH, NH), 2940 (-CH), 1705 (CO), 1665 (quinone), 1630 (quinone, chelated), 1585, 1425, 1250, 1160 cm^{-1} . 1H NMR (500 MHz, $CDCl_3$): $\delta = 1.28$ (d, $J = 6.5$ Hz, 3H, 6'-H), 2.05 (d, $J = 13.9$ Hz, 1H, 2'a-H), 2.32 (ddd, $J = 13.9, 7.9, 4.2$ Hz, 1H, 2'b-H), 3.84 (dq, $J = 6.5, 5.0$ Hz, 1H, 5'-H), 3.88 (dd, $J = 2.1$ Hz, $J = 5.0$ Hz, 1H, 4'-H), 4.03 (s, 3H, OCH_3), 4.09 (s, 3H, OCH_3), 4.55 (dd, $J = 8.3, 2.1$ Hz, 1H, 3'-H), 4.58 (d, $J = 13.7$ Hz, 1H, CH_2), 4.99 (d, $J = 13.7$ Hz, 1H, CH_2), 5.44 (d, $J = 4.2$ Hz, 1H, 1'-H), 7.21 (dd, $J = 7.8$ Hz, 1.5 Hz, 1H, 7-H), 7.27 (s, 1H, 2-H), 7.38 (br d, $J = 8.3$ Hz, 1H, 3'-NH), 7.74 (t, $J = 7.8$ Hz, 1H, 6-H), 7.96 (dd, $J = 7.8, 1.5$ Hz, 1H, 5-H), 13.68 (s, 1H, OH). ^{13}C NMR (50 MHz, $CDCl_3$): $\delta = 19.4$ (q, C-6'), 39.1 (t, C-2'), 50.9 (d, C-3'), 56.9.0 (q, OCH_3), 57.0 (q, OCH_3), 64.4 (d, C-5'), 68.4 (t, CH_2), 89.7 (C-4'), 104.0 (d, C-1'), 116.8 (s, C-1a), 117.0 (d, C-7), 118.8 (d, C-5), 120.0 (s, C-10a), 120.1 (d, C-3), 121.5 (s, C-4a), 135.2 (s, C-2), 135.9 (d, C-6), 137.4 (s, C-9a), 153.3 (s, C-1), 154.9 (s, C-4), 160.5 (s, C-8), 180.6 (s, C-9), 189.1 (s, C-10). MS: m/z (%) = 539 (19) [M+], 521 (0.5), 465 (0.5), 418 (0.5), 384 (0.5), 314 (100), 297 (39), 239 (12), 209 (6), 140 (7), 121 (8), 69 (13). HREIMS: $m/z = 539.1398$ (Calcd. for $C_{25}H_{24}F_3NO_9$, 539.1403).

1,4-Dihydroxy-5-methoxy-3-[1-*O*-(2',3',6'-trideoxy-3'-trifluoroacetamido- β -L-lyxo-hexofuranosyl)-methyl]-9,10-anthraquinone (25). From the same reaction (see 16) the rearranged glycoside 25 was isolated. Yield 49.3 mg (16.1%), mp 219-221 °C. IR: 3540, 3315 (OH, NH), 2940 (-CH), 1695 (CO), 1617, 1580 (quinone, chelated), 1440, 1255, 1180, 1053, 732 cm^{-1} . 1H NMR (400 MHz): $\delta = 1.28$ (d, $J = 6.5$ Hz, 3H, 6'-H), 2.05 (d, $J = 13.9$ Hz, 1H, 2'a-H), 2.32 (ddd,

$J = 13.9, 7.9, 4.2$ Hz, 1H, 2'-He), 3.84 (dq, $J = 6.5, 5.0$ Hz, 1H, 5'-H), 3.88 (dd, $J = 2.1$ Hz, $J = 5.0$ Hz, 1H, 4'-H), 4.09 (s, 3H, OCH₃), 4.55 (dd, $J_{3',4'} = 8.3, 2.1$ Hz, 1H, 3'-H), 4.58 (d, $J = 13.7$ Hz, 1H, CH₂), 4.99 (d, $J = 13.7$ Hz, 1H, CH₂), 5.44 (d, $J = 4.2$ Hz, 1H, 1'-H), 7.27 (s, 1H, 2-H), 7.38 (dr d, $J = 8.3$ Hz, 1H, 3'-NH), 7.42 (dd, $J = 8.9$ Hz, 1.0 Hz, 1H, 6-H), 7.81 (dd, $J = 8.9, 7.8$ Hz, 1H, 7-H), 8.08 (dd, $J = 7.8, 1.8$ Hz, 1H, 8-H), 12.86 (s, 1H, OH), 13.75 (s, 1H, OH). MS: $m/e = 525$ (2/M⁺); 524 (11, M-H⁺); 300 (100), 284 (42), 283 (68), 282 (62), 271 (13), 240 (4). HREIMS: $m/z = 525.1243$ (Calcd. for C₂₄H₂₂F₃NO₉, 525.1247).

1,4,5-Trihydroxy-3-[1-O-(2',3',6'-trideoxy-3'-trifluoroacetamido-β-L-lyxo-hexofuranosyl)-methyl]-9,10-anthraquinone (26) (see 17). IR: 3420, 3290 (OH, NH), 2980, 2930 (-CH), 1705 (CO), 1605 (quinone, chelated), 1435, 1255, 1178, 725 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.29$ (d, $J = 6.5$ Hz, 3H, 6'-H), 1.97 (d, $J = 5.7$ Hz, 1H, 5'-OH), 2.06 (d, $J = 14$ Hz, 1H, 2'-H), 2.33 (ddd, $J = 14.0, 7.7, 4.2$ Hz, 1H, 2'e-H), 3.85 (ddd, $J_{4',5'} = 6.5, 5.7, 5.0$, 1H, 5'-H), 3.89 (dd, $J = 5.0, 2.0$ Hz, 1H, 4'-H), 4.56 (d, $J = 14$ Hz, 1H, CH₂), 4.58 (br d, $J =$ Hz, 1H, 3'-H), 5.00 (d, $J = 14.0$ Hz, 1H, CH₂), 5.45 (d, $J = 4.0$ Hz, 1H, 1'-H), 7.39 (br d, $J = 8.0$ Hz, 1H, 3'-NH), 7.32-7.92 (m, 4H, aromatic H), 12.12 (s, 1H, OH), 12.78 (s, 1H, OH), 13.00 (s, 1H, OH). EIMS (180 °C): m/z (%) = 511 (6) [M⁺], 467 (1), 437 (3), 354 (2), 324 (3), 286 (96), 270 (100), 241 (24), 213 (10), 180 (10), 169 (18), 155 (24), 140 (40), 113 (20), 86 (75). HREIMS: $m/z = 511.1089$ (Calcd. for C₂₃H₂₀F₃NO₁₂, 511.1090).

1,4-Dihydroxy-2-[1-O-(2,3,6-trideoxy-3-trifluoroacetamido-α-L-lyxo-hexopyranosyl)-butyl]-9,10-anthraquinone (nonpolar) (28). The glycosylation was performed as described in the general procedure starting with 51 mg (0.16 mmol) of aglycone 27⁶² to afford 23 mg (26 %) of the less polar glycoside, mp 225 °C. IR: 3450 (OH, NH), 1710 (C=O), 1621 (quinone, chelated), 1586 (arom.) cm⁻¹. ¹H NMR (500 MHz, CDCl₃): $\delta = 0.89$ (d, $J = 6.6$ Hz, 3H, 6'-H), 0.94 (t, $J = 7.4$ Hz, 3H, CH₂CH₃), 1.30 - 1.47 (m, 2H, CH₂), 1.70-1.86 (m, 2H, CH₂), 1.82 (dt, $J = 13.2$ Hz, $J = 4.0$ Hz, 1H, 2'b-H), 1.85 (d, $J = 8.0$ Hz, 1H, -OH), 2.08 (dd, $J = 13.2, J = 5.2$ Hz, 1H, 2'a-H), 3.54 (br d, $J = 6.0$ Hz, 1H, 4'-H), 3.85 (br q, $J = 6.4$ Hz, 1H, 5'-H), 4.42 (m, 1H, 3'-H), 5.10 (d, $J = 3.8$ Hz, 1H, 1'-H), 5.13 (dd, $J = 7.2, J = 5.3$ Hz, 1H, CHCH₂), 6.69 (br d, $J = 8.0$ Hz, 1H, NH), 7.46 (s, 1H, 3-H), 7.85 (m, 2H, 6-H, 7-H), 8.36 (m, 2H, 5-H, 8-H), 12.88 (s, 1H, -OH), 13.39 (s, 1H, -OH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 13.9$ (q, C-6'), 16.1 (q, CH₂CH₃), 18.5 (t, CH₂CH₃), 29.8 (t, C-2'), 37.6 (t, CHCH₂), 46.2 (d, C-3'), 66.2 (d, C-5'), 69.0 (d, C-4'), 73.3 (d, CHCH₂), 97.4 (d, C-1'), 111.9 (s, C-10a), 112.4 (s, C-4a), 126.1 (d, C-3), 127.0 (d, C-5), 127.1 (d, C-8), 133.5 (s, C-9a), 133.6 (s, C-8a), 134.2 (d, C-7), 134.5 (d, C-6), 144.2 (s, C-2), 152.2 (s, C-4), 157.6 (s, C-1), 186.5 (s, C-10), 187.3 (s, C-9); Anal. Calcd for C₂₆H₂₆NO₈F₃ (537.5): C, 58.10; H, 4.88; N, 2.61. Found: C, 57.93; H, 4.92; N, 2.74%.

1,4-Dihydroxy-2-[1-O-(2,3,6-trideoxy-3-trifluoroacetamido-α-L-lyxo-hexopyranosyl)-butyl]-9,10-anthraquinone (polar) (29). In the same reaction (see 28) 22 mg (25 %) of the polar α-glycoside 29 was isolated, mp (softening) 128 °C. IR: 3420 (OH, NH), 1717 (C=O), 1623 (quinone, chelated), 1588 cm⁻¹ (aromat). ¹H NMR (270 MHz): $\delta = 0.98$ (t, $J = 7.2$ Hz, 3H, CH₂CH₃), 1.31 (d, $J = 6.5$ Hz, 3H, 6'-H), 1.33-1.63 (m, 2H, CH₂), 1.75 (t, $J = 7.0$ Hz, 2H, CH₂), 1.78 (dt, $J = 13.4, 3.5$ Hz, 1H, 2'a-H), 2.02 (dd, $J = 13.4, 5.2$ Hz, 1H, 2'e-H), 3.67 (m, 1H, 3'-H),

4.24 (q, $J = 6.5$ Hz, 1H, 5'-H), 4.53 (m, 1H, 3'-H), 4.75 (d, $J = 3.5$ Hz, 1H, 1'-H), 6.71 (br d, $J = 8.0$ Hz, 1H, NH), 7.39 (s, 1H, 3-H), 7.86 (m, 2H, 6-H, 7-H), 8.34 (m, 2H, 5-H, 8-H), 12.91 (s, 1H, OH), 13.43 (s, 1H, 2 OH). EIMS (180 °C): m/z (%) = 537 (3) [M⁺], 442 (2), 312 (93), 269 (100), 253 (19), 225 (12), 155 (16), 113 (11), 77 (6). HREIMS: $m/z = 537.1614$ (Calcd. for C₂₆H₂₆F₃NO₈, 537.1611).

2,3-Bis-[O-(2,3,6-trideoxy-3-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-1,4-dihydroxy-9,10-anthraquinone (31). The glycosylation of aglycone **30**^{55,56} 60 mg (0.2 mmol) was performed as in the general procedure to afford 36 mg (24 %) of bis- α -glycoside **31**, mp 130 °C (softening). IR: 3420 (OH, NH), 1719 (C=O), 1623 (quinone, chelated), 1589 cm⁻¹ (arom.). ¹H NMR(250 MHz, CDCl₃): $\delta = 1.18$ (d, $J = 6.5$ Hz, 6H, 6'-H), 1.74 –2.18 (m, 1H, 2'a-H, 2'e-H), 3.62 (m, 2H, 3'-H), 4.23 (q, $J = 6.5$ Hz, 2H, 5'-H), 4.42 (m, 2H, 3'-H), 4.78 (d, $J = 11.2$ Hz, 1 H, CH₂), 4.94 (d, $J = 11.2$ Hz, 1H, CH₂), 5.15 (m, $J = 4.0$ Hz, 2H, 1'-H), 6.77 (d, $J = 8.4$ Hz, 2H, NH), 7.84 (m, 2H, 6-H, 7-H), 8.36 (m, 2H, 5-H, 8-H), 13.52 (s, 2H, 2 OH). Anal. Calcd for C₃₂H₃₂N₂O₁₂F₆ (750.62): C, 51.21; H, 4.30; N, 3.73. Found: C, 50.97; H, 4.28; N, 3.75%.

1,5-Dihydroxy-2,6-bis-[l-O-(2'-,3',6'-trideoxy-3'-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-methyl]-9,10-anthraquinone (33) and the mixed α -L-lyxo-hexopyranosyl- β -L-lyxo-furanoside glycoside (34). Aglycone **32**⁵⁴ (200 mg, 0.67 mmol) was glycosylated as described in the general procedure using 940 mg (2.17 mmol) of sugar **2** and 780 mg (3.04 mmol) of silver triflate to afford 84.1 mg (24%) of less polar bis- α -glycoside **33**, mp 258-260 °C and 30.8 mg (9%) of the polar mixed glycoside, **34**, mp 238-240 °C.

Data for 33. IR: 3430, 3290 (OH, NH), 2978, 2938 (-CH), 1710 (CO), 1630 (quinone, chelated), 1425, 1257, 1170, 980, 800 cm⁻¹. ¹H NMR (250 MHz, CDCl₃): $\delta = 1.27$ (d, $J = 6.5$ Hz, 6H, 2 x 6'-H), 1.86 (dt, $J = 12.8, 3.7$ Hz, 2H, 2 x 2'-Ha), 2.08 (ddd, $J = 12.8, 6.0, 1.0$ Hz, 2H, 2 x 2'-He), 3.64 (dd, $J = 8.4, 2.4$ Hz, 2H, 2 x 4'-H), 4.15 (q, $J = 6.5$ Hz, 2 x 5'-H), 4.51 (dddd, $J = 12.8, 8.0, 2.4, 6$ Hz, 2H, 2 x 3'-H), 4.66 (d, $J = 14.3$ Hz, 2H, 2 x CH₂), 4.90 (d, $J = 14.3$ Hz, 2H, 2 x CH₂), 5.08 (dd, $J = 3.7, 1.0$ Hz, 2H, 2 x 1'-H), 6.71 (d, $J = 8$ Hz, 2H, 2 x 4'-NH), 7.84 (d, $J = 7.9$ Hz, 2H, 3-H, 7-H), 7.88 (d, $J = 7.9$ Hz, 2H, 4-H, 8-H), 13.04 (s, 2H, 1-OH, 5-OH). ESIMS: 750 (37) [M⁺], 749 (100) [M⁺ - 1]; HREIMS: m/z (%) = 773.1751 (Calcd. for C₃₂H₃₂F₆N₂O₁₂ + Na, 773.1752). **Data for 34.** IR: 3410, 3300 (NH, OH), 2978, 2920 (-CH), 1712 (CO), 1630 (quinone, chelated), 1430, 1250, 1170, 980, 800 cm⁻¹. ¹H NMR (CDCl₃, 500 MHz): $\delta = 1.27$ (d, $J = 6.5$ Hz, 6H, 6'-H, 6''-H), 1.85 (dd, $J = 3.9, 1$ Hz, 2'-Ha), 1.92 (d, $J = 13.5$ Hz, 1H, 2''-Ha), 2.08 (ddd, $J = 1.0, 6.5, 12.8$ Hz, 1H, 2'-He), 2.28 (ddd, $J = 4.3, 13.5, 7.8$ Hz, 1H, 2''-He), 3.63 (br s, 1H, 4'-H), 3.83 (ddq, $J = 5.1, 5.9, 6.5$ Hz, 1H, 5''-H), 3.86 (dd, $J = 2.2, 5.1$ Hz, 1H, 4''-H), 4.13 (q, $J = 6.5$ Hz, 1H, 5'-H), 4.53 (m, 2H, 3'-H, 3''-H), 4.55 (d, $J = 12.2$ Hz, 1H, CH₂), 4.66 (d, $J = 14.4$ Hz, 1H, CH₂), 4.90 (d, $J = 14.4, 1$ Hz, CH₂), 5.00 (d, $J = 12.2$ Hz, 1H, CH₂), 5.07 (d, $J = 3.8$ Hz, 1H, 1'-H), 5.44 (d, $J = 4.0$ Hz, 1H, 1''-H), 6.75 (d, $J = 8.1$ Hz, 1 H), 7.40 (d, $J = 8.1$ Hz, 1H, NH), 7.87 (m, 4H, H-3, H-4, H-7, H-8), 12.96 (s, 1H, OH), 13.18 (s, 1H, OH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 16.6$ (q, C-6'), 19.4 (q, C-6''), 29.7 (t, C-2'), 38.9 (t, C-2''), 46.2 (d, C-3'), 50.9 (d, C-3''), 63.5 (d, C-5'), 64.0 (d, C-5''), 66.0 (d, CH₂), 68.4 (d, CH₂), 89.8 (d, C-4''), 96.7 (d, C-1'), 103.9 (d, C-1''), 115.4 (s, C-1a, C-9a), 118.0 (s, C-4a, C-10a), 119.0 (d, C-4), 199.3 (d, C-8), 132.1 (s, C-2),

132.8 (s, C-6), 134.6 (d, C-3), 135.0 (d, C-7), 160.3 (s, C-1), 160.8 (s, C-5), 187.9 (s, C-9), 188.0 (s, C-10). EIMS (180 °C): m/z (%) = 750 (0.5) [M^+], 732 (0.5), 706 (0.5), 676 (0.5), 621 (1), 604 (2), 593 (1), 508 (39), 300 (85), 284 (100), 266 (82), 226 (23), 113 (60). EIMS: 750 (42) [M^+], 749 (100) [M^+-1]; HREIMS: m/z (%) = 773.1750 (Calcd. for $C_{32}H_{32}F_6N_2O_{12} + Na$ 773.1752).

7-O-(2,3,6-Trideoxy-3-trifluoroacetamido- α -L-lyxo-hexopyranosyl)-steffimycinone (36).

Steffimycinone (4.1 mg, 0.01 mmol) (**35**) was converted to the glycoside as described in the general procedure to afford 4.3 mg (67 %) of **36**. 1H NMR: δ = 1.23 (d, $J_{5',6'}$ = 6.6 Hz, 3 H, 6'-H), 1.59 (s, 3 H, CH_3), 1.91 (dt, $J_{2'a,2'e}$ = 13.2, $J_{2'a,3'}$ = 12.4, $J_{1',2'a'}$ = 3.7 Hz, 1 H, 2'a-H), 2.07 (dd, $J_{2'a,2'e}$ = 13.2, $J_{2'e,3'}$ = 5.0 Hz, 1 H, 2'e-H), 3.55 (s, 3 H, OCH_3), 3.64 (m, 1 H, 4'-H), 3.71 (m, 1 H, 8-H), 3.98 (s, 3 H, OCH_3), 4.24 (q, $J_{5,6'}$ = 6.6 Hz, 1 H, 5'-H), 4.44 (m, 1 H, 3'-H), 5.24 (m, $J_{combined}$ = 9 Hz, 1 H, 7-H), 5.64 (d, $J_{1',2'a}$ = 3.7 Hz, 1 H, 1'-H), 6.73 (d, $J_{1,3}$ = 2.4 Hz, 1 H, 3-H), 6.77 (d, $J_{3',NH}$ = 8.5 Hz, 1 H, NH), 7.44 (d, $J_{1,3}$ = 2.4 Hz, 1 H, 1-H), 8.35 (s, 1 H, 11-H), 12.11 (s, 1 H, 4-OH), 12.91 (s, 1 H, 6-OH). EIMS (180 °C): m/z (%) = 639 (2) [M^+], 477, (3), 451 (9), 414 (16), 396 (30), 621 (1), 353 (63), 593 (1), 324 (25), 226 (100). HREIMS: m/z (%) = 639.1564 (Calcd. for $C_{29}H_{28}F_3NO_{12}$, 639.1564).

Acknowledgements

We thank the German Science Foundation (DFG) for financial support and Prof. Federico-Maria Arcamone for helpful suggestions and gift of daunosamin hydrochloride.

References

1. Zhang, G.; Fang, L.; Zhu, L.; Zhong, Y.; Wang, P. G.; Sun, D. *J. Med. Chem.* **2006**, *49*, 1792 and references therein.
2. Kelly, T. R. *Ann. Rep. Med. Chem.* **1979**, *14*, 288.
3. Broadhurst, M. J.; Hassall, C. H.; Thomas, G. J. *Chem. and Ind.* **1985**, 106.
4. Krohn, K. *Angew. Chem.* **1986**, *98*, 788-787; *Angew. Chem. Int. Ed.* **1986**, *25*, 790.
5. Stoodley, R. J. *Second SCI/RSC Medical Chemistry Symposium*; Spec. Publ. Royal Society of Chemistry, Cambridge, 1984, p134.
6. Thomson, R. H., *Naturally Occurring Quinones III. Recent Advances*, Chapman and Hall: London, 1987; pp 345-526.
7. Tamura, Y.; Kita, Y. *J. Syn. Org. Chem. (Japan)* **1988**, 205.
8. Krohn, K.; Ekkundi, V. S., *Total Synthesis of Enantiomerically Pure Anthracyclines in Studies in Natural Product Chemistry, Stereoselective Synthesis Vol. 4 (Part C)* Atta-ur-Rahman, Ed., Elsevier: Amsterdam, 1989, pp 317-366.

9. Krohn, K. *Building Blocks for the Total Synthesis of Anthracyclines* In *Progr. Chem. Org. Nat. Prod.* Vol. 48, Herz, W.; Grisebach, H.; Kirby, G. W.; Tamm, Ch., Eds., Springer; Wien and New York, 1989; pp 37-88.
10. Kelly, T. R. Ed.; *Tetrahedron Symposia in Print No. 17* **1984**, 40, 4537.
11. Lown, J. W. *Chem. Rev.* **1993**, 165.
12. Krohn, K. *Eur. J. Org. Chem.* **2002**, 1351.
13. Cambie, R. C.; Rutledge, P. S.; Woodgate, P. D. *Austral. J. Chem.* **1992**, 45, 483.
14. Brockmann, H. *Fortsch. Chem. Org. Naturst.* **1963**, 21, 121.
15. El Khadem, H. S., *Anthracycline Antibiotics*, Academic Press: New York, 1982.
16. Abdella, B. R. J.; Fisher, J. *Environ. Health Perspect.* **1985**, 64, 3.
17. Arcamone, F. *Doxorubicin*, Academic Press: New York, 1981.
18. *Anthracyclines. Current Status and New Developments*; Crooke, S. T.; Reich, S. D., Eds.: Academic Press: New York, 1980.
19. Gesson, J.-P.; Mondon, M. *Actual. Chim. Thér.* **1986**, 13, 161.
20. Arcamone, F. *Cancer Res.* **1985**, 45, 5995.
21. Arcamone, F. *The Development of New Antitumor Anthracyclines in Anticancer Agents based on Natural Products Models*, Cassidy, J. M.; Dowes, J. D. Eds, vol. 16, Academic Press: New York, 1980, pp 1-41.
22. Strauss, D. G. *Pharmazie* **1987**, 42, 289.
23. Priebe, W. Ed; *Anthracycline Antibiotics, New Analogues, Methods of Delivery, and Mechanisms of Action*, in *ACS Symposium Series*, Vol. 574, 1995.
24. Suarato, A.; Angelucci, F.; Bargiotti, A. *Chim. Oggi* **1990**, 8, 9.
25. Ikeda, D.; Ajito, K. *Yuki Gosei Kagaku Kyokaishi* **1991**, 49, 1002.
26. Takagi, Y.; Tsuchiya, T.; Miyake, T.; Takeuchi, T.; Umezawa, S. *Yuki Gosei Kagaku Kyokaishi* **1992**, 50, 131.
27. Monneret, C. *Ann. Pharm. Fr.* **1997**, 55, 5.
28. Taatjes, D. J.; Fenick, D. J.; Gaudiano, G.; Koch, T. H. *Curr. Pharm. Des.* **1998**, 4, 203.
29. Vogel, P. *Curr. Org. Chem.* **1998**, 2, 255.
30. Arcamone, F.; Cassinelli, G. *Curr. Med. Chem.* **1998**, 5, 391.
31. Suarato, A.; Angelucci, F.; Geroni, C. *Curr. Pharm. Des.* **1999**, 5, 217.
32. Michel, S.; Desbene, S.; Gesson, J.-P.; Monneret, C.; Tillequin, F. *Stud. Nat. Prod. Chem.* **2000**, 21, 157.
33. Monneret, C. *Eur. J. Med. Chem.* **2001**, 36, 483.
34. Binaschi, M.; Bigioni, M.; Cipollone, A.; Rossi, C.; Goso, C.; Maggi, C. A.; Capranico, G.; Animati, F. *Curr. Med. Chem.: Anti-Cancer Agents* **2001**, 1, 113.
35. Le Sann, C. *Nat. Prod. Rep.* **2006**, 23, 357.
36. (a) Arcamone, F. C., *Anthracyclines in Anticancer Agents from Natural Products*; Gragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds.; Taylor & Francis, Boca Raton, 2005, pp 299-320. (b) *Anthracyclines, Chemistry and Biology*, in *Topics Curr. Chem.*: Krohn, K., Ed.; Springer: Heidelberg, 2008; Vol. 1.

37. Kita, Y.; Kirihara, M.; Sekihachi, J.; Okunaka, R.; Sasho, M.; Mohri, S.; Honda, T.; Akai, S.; Tamura, Y.; Shimooka, K. *Chem. Pharm. Bull.* **1990**, *38*, 1836.
38. Menyhart, M.; Koeber, K.; Sztaricskai, F. *J. Carbohydr. Chem.* **1990**, *9*, 253.
39. Olsufyeva, E. N.; Backinowsky, L. V. *Tetrahedron Lett.* **1990**, *31*, 4805.
40. Kita, Y.; Kirihara, M.; Fujii, Y.; Okunaka, R.; Akai, S.; Maeda, H.; Tamura, Y.; Shimooka, K.; Ohishi, H.; Ishida, T. *Chem. Pharm. Bull.* **1991**, *39*, 857.
41. Tolstikov, G. A.; Shul'ts, E. E.; Vafina, G. F.; Spirikhin, L. V. *Zh. Org. Khim.* **1992**, *28*, 192.
42. Acosta, J. C.; Caballero, E.; Gravalos, D. G.; Medarde, M.; Sahagun, H.; Stoodley, R. J.; Tome, F. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 2955.
43. Cameron, D. W.; Feutrill, G. I.; Griffiths, P. G. *Aust. J. Chem.* **2000**, *53*, 25.
44. Rho, Y. S.; Kim, W.-J.; Yoo, D. J.; Kang, H. S.; Chung, S.-R. *Bull. Korean Chem. Soc.* **2001**, *22*, 963.
45. Priebe, W.; Grynkiewicz, G.; Neamati, N. *Monatsh. Chem.* **1991**, *122*, 419.
46. Cameron, D. W.; Griffiths, P. G. *Tetrahedron Lett.* **1993**, *34*, 4685.
47. Toshima, K.; Hasegawa, M.; Shimizu, J.; Matsumura, S. *ARKIVOC* **2004**, *xiii*, 28.
48. Horton, D.; Weckerle, W. *Carbohydr. Res.* **1975**, *44*, 227.
49. Hanessian, S.; Banoub, J. *Carbohydr. Res.* **1975**, *44*, C14.
50. (a) Arcamone, F.; Bargiotti, A.; Cassinelli, G.; Redaelli, S.; Hanessian, S.; Di Marco, A.; Casazza, A. B.; Dasdia, T.; Necco, A.; Reggiani, P.; Supino, R. *J. Med. Chem.* **1976**, *19*, 733. (b) Broadhurst, M. J.; Hassall, C. H.; Thomas, G. J. *Chem. Commun.* **1982**, 158. (c) Di Marco, A.; Casazza, A. M.; Giuliani, F.; Pratesi, G.; Arcamone, F.; Bernardi, L.; Franchi, G.; Giardino, P.; Patelli, B.; Penco, S. *Cancer Treat. Rep.* **1978**, *62*, 375.
51. Arcamone, F.; Bernardi, L.; Patelli, B.; Giardino, P.; Di Marco, A.; Casazza, A. M.; Soranzo, C.; Pratesi, G. *Experientia* **1978**, *34*, 1255.
52. Arcamone, F. *Lloydia* **1977**, *40*, 45.
53. Brederbeck, K.; Banzhaf, L.; Koch, E. *Chem. Ber.* **1972**, *105*, 1062.
54. Brederbeck, K.; Metwally, S. A.; Koch, E.; Weckmann, R. *Liebigs Ann. Chem.* **1975**, 972.
55. Krohn, K.; Hemme, C. *Liebigs Ann. Chem.* **1979**, 19.
56. Krohn, K.; Hemme, C. *Liebigs Ann. Chem.* **1979**, 35.
57. El Khadem, H.; Matsuura, D. *Carbohydr. Res.* **1982**, *99*, 143.
58. Kelly, R. C.; Schletter, I.; Koert, J. M.; MacKellar, F. A.; Wiley, P. F. *J. Org. Chem.* **1977**, *42*, 3591.
59. Krohn, K.; Behnke, B. *Chem. Ber.* **1980**, *113*, 2994.
60. Krohn, K.; Klimars, M.; Köhle, H. J.; Ebeling, E. *Tetrahedron* **1984**, *40*, 3677.
61. Krohn, K.; Müller, U.; Priyono, W.; Sarstedt, B.; Stoffregen, A. *Liebigs Ann. Chem.* **1984**, 306.
62. Jin, G.-Z.; Song, G.-Y.; Zheng, X.-G.; Kim, Y.; Sok, D.-E.; Ahn, B.-Z. *Arch. Pharm. Res.* **1998**, *21*, 198; *Chem. Abstr.* **1998**, *129*, 36203.